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Background and Objectives: In pulmonary tuberculosis, bacteriological status at two months
affects subsequent treatment and prognosis. The effect on treatment outcome and risk fac-
tors for sputum conversion at two months treatment in previously untreated pulmonary
tuberculosis (PTB) patients was studied in the following report.
Methods: A 1:1 case-control studywas performed from June 2006 to February 2008 on patients
in the Revised National Tuberculosis Control Program in a tertiary level institute in Delhi,
India. Patients with previously untreated PTB with sputum smear positive at 2 months of
treatment (cases) were compared with those who achieved conversion (controls).
Results: In 74 cases and 74 controls, independent risk factors for sputum smear positive at
two months were: illness for >2 months, presence of cavity or extensive disease on chest
X-ray, and interruption in intensive phase of treatment. Patients with smear positive at 2
or 3 months of treatment were more likely to fail or default from treatment. Aforesaid fac-
torswere also associatedwith sputum culture positive status at 2 months in univariate anal-
ysis. Patients who interrupted treatmentP3 times in the first two months were more likely
to be culture positive at two months and had a higher rate of default and failure.
Conclusions: Illness for more than 2 months, presence of cavity or extensive disease on chest
X-ray, and interruption in intensive phase of treatment are independent risk factors for spu-
tum smear positivity at two months, which in turn is associated with poor treatment out-
comes. Patients with these factors merit special attention under the national program.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
In the Revised National Tuberculosis Control Program (RNTCP)
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uberculosis and Respiratsmear-positive patients with pulmonary tuberculosis (PTB)
are treated with a regimen consisting of an initial intensive
phase (IP) of 2 months of thrice-weekly isoniazid (H), rifampi-
cin (R), pyrazinamide (Z) and ethambutol (E) followed bybacteriology. Published by Elsevier Ltd. All rights reserved.
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the Directly Observed Treatment Short Course Strategy
(DOTS). At the end of 2, 4 and 6 months of treatment, two di-
rect sputum smears for acid-fast bacilli (AFB) are performed.
In patients who remain smear positive at two months, the
intensive phase is extended for one more month after which
they are put on continuation phase irrespective of the smear
status [1].
The bacteriological status at 2 months is an important
milestone in the management of PTB patients. It influences
subsequent treatment to be given to the patient [1–3]. Persis-
tent sputum smear positivity at 2 months presages poor out-
come, higher rates of treatment failure, and relapse [1,4,5].
Further, patients who harbor multi drug-resistant strains
may be more likely to be positive at two months of treatment
under DOTS [6].
In intermittent therapy, missing the dose on its due date
can challenge the efficacy of the regimen since the increased
gap may not be sufficient to sustain the lag period [7]. This
interruption in treatment may ultimately lead to failure of a
given anti-tuberculosis (ATT) regimen [6,8]. The effect of
missing single or multiple ATT doses in the first two months
on bacteriological status at two months of treatment was not
previously known.
The primary aim of the present study is to study clinical,
radiological and bacteriological factors that may be associ-
ated with sputum smear positivity at the end of two months
of treatment under RNTCP. The influence of interruption of
treatment on sputum positivity at two months and on treat-
ment outcome was also analyzed.
Materials and methods
A 1:1, case-control study was performed from June 2006 to
February 2008 on patients enrolled in the RNTCP in Lala
Ram Sarup Institute of Tuberculosis and Respiratory Diseases,
a tertiary level national TB institute in South Delhi, India. The
study was reviewed and approved by the ethics and research
committee of the Institute. The study group consisted of new
sputumAFB smear-positive PTB patients started on treatment
under RNTCP. The patients were enrolled in the study at the
end of the initial two months of treatment.
The ‘cases’ were comprised of patients whose sputum di-
rect smear was positive for AFB after 2 months of treatment.
Sputum was examined and graded per RNTCP guidelines as:
scanty, 1+, 2+, 3+ or negative [1]. The ‘controls’ were com-
prised of patients whose sputum direct smear was negative
after two months of treatment. The control group was
matched by age and sex. As far as possible, the controls were
selected from the same DOTS center and within a month of
the date of registration of the cases. The cases and controls
were followed-up until treatment completion, and treatment
outcome was recorded. Informed consent was obtained and a
standardized Performa was filled out.
The data regarding the duration of illness prior to starting
treatment; tobacco smoking, alcohol intake, socioeconomic
status [9], associated diabetes mellitus (DM), body mass index
(BMI), human immune-deficiency virus (HIV) status and
radiological extent of disease at enrollment were collected.If any dose of ATTwas missed in the intensive phase, it was
counted as ‘treatment interrupted’. In RNTCP, these doses
are subsequently given and the total number of doses in the
regimen is completed. The patients were advised to provide
two sputa (spot and early morning), which were stained by
Ziehl Nelson method for AFB and also cultured for Mycobacte-
rium tuberculosis on Lowenstein-Jensen medium. Positive cul-
tures were subjected to drug susceptibility testing (DST) by
using the absolute concentration method. The minimum
inhibitory concentration (MIC) of the drugs used was as fol-
lows: SM 16 lg/ml, INH 0.4 lg/ml, RMP 128 lg/ml and EMB
8 lg/ml.
The data for radiological extent of disease was collected in
the categories mentioned by NTA [10], but for data analysis,
the category ‘far advanced’ was compared with the aggrega-
tion of ‘less advanced’ and ‘minimal’ category, termed as ‘less
advanced’ in this study. Similarly, data for initial sputum
grade was collected as per RNTCP definitions [1], but, for anal-
ysis, sputum grade 3+ was compared with the aggregate of
‘2+, 1+ and scanty’ termed as ‘non-3+’.
Data was analyzed in SPSS version 12.0 (SPSS Inc., Chicago,
IL). For parametric data – t test for independent samples and
Analysis of Variance; for nominal data – Pearson’s chi square
test or fisher’s exact test was used. For hypothesis testing, a
probability of 0.05 was considered significant. Those variables
which were significant on univariate analysis were tested for
independent association using binary logistic regression.
Results
In the study period, data from 74 cases and 74 controls was
obtained. Table 1 shows the clinical, bacteriological and radio-
logical profile of cases and controls. On univariate analysis
(Table 1), it was found that patients who were smear positive
at two months did not differ significantly with respect to age,
sex, associated DM or HIV, smoking and alcohol use from
those who were smear negative at two months. The patients
who were smear positive at two months were significantly
more likely to have been ill for more than 2 months, to have
lower BMI, to have cavity and far-advanced disease on chest
X-ray, to have initial sputum smear grade 3+, and to be an
interrupter than the controls.
On binary logistic regression (Table 2), it was found that
more than 2 months’ duration of illness, cavity on chest X-
ray, far advanced disease radiologically, and occasional and
frequent interruption were the risk factors independently
associatedwith being smearpositive at 2 months of treatment.
However, low body mass index and initial sputum grade were
not independent risk factors (not shown in Table 2).
The culture and DST results of 74 smear positive cases at
twomonths are shown in Fig. 1. Among them, culturewas po-
sitive in 30 (40.5%) patients; 7 had MDR-TB; 9 were pan-sensi-
tive; and 9 had non-MDR-TB. In two patients the culture was
contaminated. In five culture positive patients the DST was
contaminated.
The culture positivity among smear positive patients rep-
resents the presence of live bacilli. On univariate analysis of
a total of 148 cases and controls, it was observed that all
the factors associated with smear positivity at two months
Table 1 – Univariate analysis of profile of cases and controls at 2 months of treatment.
Variable Sm + 2 M (case) Sm  2 M (control) P for
testb
Un-adjusted
odds ratio (OR)
95% CI
N = 74 %a N = 74 %a
Age (mean) 34.7 – 32.9 – 0.43 1.01 0.99–1.04
Sex Male 53 71.6 53 71.6 1.00 1.00 0.49–2.04
Female 21 28.4 21 28.4 Reference
category
Duration of illnessc <2 months 36 48.6 70 94.6 <0.001 Reference
category
>2 months 38 51.4 4 5.4 18.5 6.11–55.82
Diabetes mellitus Present 6 8.1 4 5.4 0.51 1.544 .417–5.71
HIV Present 2 2.7 1 1.35 0.567 2.028 .180–22.86
Smoking Present 32 43.2 20 27.0 0.058 2.06 1.03–4.10
Alcohol intake Present 18 24.3 18 24.3 1.00 1.00 0.47–2.12
Body mass index (mean) 16.83 18.24 0.006 0.86 0.77–0.96
Cavity Present 70 94.6 27 36.5 <0.001 30.46 10.00–92.73
Radiological extent
of diseased
Far advanced 58 78.4 10 13.5 <0.001 23.2 9.76–55.17
Less advanced 16 21.6 64 86.5 Reference
category
Initial sputum AFB smear
gradee
3+ 53 71.6 25 33.8 <0.001 4.95 2.46–9.94
Non 3+ 21 28.4 49 66.2 Reference
category
Any Interruption in IP yes 40 54.1 25 33.8 0.020 2.30 1.19–4.48
Number of Interruptions in
treatment in IPf
Nil 34 45.9 50 67.6 0.002 Reference
category
1–2 ‘occasional’ 24 32.4 21 28.4 1.68 0.81–3.49
3 or more ‘frequent’ 16 21.6 3 4.1 7.84 2.12–29.00
Sputum AFB Culture at
end of two monthsg
Positive 30 40.5 0 0 <0.001 Not
applicableh
a Percentage out of cases or controls respectively.
b For parametric data – t test for independent samples and Analysis of Variance; for nominal data – Pearson’s chi square test or fisher’s exact test;
for ordinal data – Mann Whitney U test and kruskal wallis H test.
c Duration of illness prior to diagnosis.
d ‘Less advanced disease’: minimal or moderately advanced disease10, see materials and methods.
e Initial sputum grade ‘non 3+’ consists of ‘scanty+’ or ‘1+’ or ‘2+’.
f Number of patients with this number of interruptions in IP.
g Among cases, in 30 (40.5%) patients, culture was positive; in 42 (56.8%) patients culture was negative and in 2 (2.7%) patients, culture was
contaminated. Among controls, in 73 (98.6%) patients culture was negative and in 1 (1.3%) patient culture was contaminated.
h Sputum AFB sample taken at end of two months; Odds ratio cannot be calculated due to zero culture positive among controls.
Table 2 – Binary logistic regression analysis of variables found significant on univariate analysis that are known at the start of
category I.
Factors Adjusted odds ratio (aOR) 95% CI for aOR P value
Duration of illness >2 mo 8.292 2.103–32.703 0.003
Cavity 10.806 2.422–48.219 0.002
Radiological extent of disease 10.8 3.119–37.39 <0.001
Number of Interruptions in treatment in IP 1–2 4.737 1.214–18.491 0.025
Number of Interruptions in treatment in IP 3 or more 15.559 2.145–112.88 0.007
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(Table 3). Multivariate analysis was not done owing to paucity
of numbers in the culture positive subgroup.
All the patients were followed up, and the outcome of
treatment of patients with smear positive results at two
months was compared with patients with smear negative re-
sults at two months (Table 4). Out of the 74 patients with
smear positive results at two months, 27 (36.5%) patients re-
mained smear positive at three months; 47 (63.5%) patientswere cured; and 20 (27%) patients failed treatment. Compari-
son of treatment outcome of patients whose sputa were posi-
tive at two or three months with those who achieved sputum
conversion at two or three months showed that the former
group had lower cure rates and more defaults, failures and
deaths (P < 0.001, Fisher’s exact test).
Table 5 shows analysis of treatment interrupters in the
intensive phase. Out of a total of 148 patients under study,
84 (56.8%) did not interrupt treatment. There was progres-
Negative
42 (57%)
Others
7 (10%)
MDR
7 (9%)
non-MDR
9 (12%)
Pansensitive
9 (12%)
Fig. 1 – Culture and DST of smear positive sputa collected at
two months of treatment.
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for linear trend < 0.001). The interrupters had higher chances
of being smear positive at two months (P = 0.038) compared
with non-interrupters. Patients who interrupted treatment
once or twice were counted together as ‘occasional interrupt-
ers’ and patients who interrupted treatment thrice or more
were counted together as ‘frequent interrupters’. There were
45 (30.4%) occasional interrupters and 19 (12.8%) frequent
interrupters (P for linear trend = 0.014).Table 3 – Factors associated with a 2 month positive culture res
Factorsa Culture pos. 2 month Culture neg
n %b n %
Duration of illness >2 mo 13 37.3 28 2
Cavity 30 100 65 5
Extensive disease 26 86.7 40 3
Sputum smear 3+ 24 80 52 4
Occasional interrupter 9 30 35 3
Frequent interrupter 8 26.7 10
a See Table 1 legend for explanation of variables.
b Out of 30.
c Out of 115 (out of total 148 patients, 30 had positive culture, 3 had cultu
d n.d: Not done because no patients with culture positive without cavity.
Table 4 – Outcome of patients remaining smear positive at 2 mo
Type
Smear positive at two monthsf Totalc
Smear positive at 3 monthsa,
Smear negative at 3 monthsa
Smear negative at two monthsf
a Sputum smear examination at 3 months done only for patients with sm
b One default before 3 months in cases.
c Percentage out of 74.
d Percentage out of 27.
e Percentage out of 46.
f Fisher’s exact test for smear positive at two months compared with sme
g Fisher’s exact test for smear positive at three months compared with smTable 6 shows the culture, DST and treatment outcomes
for patients who interrupted treatment. Frequent interrupters
had significantly higher rates of being culture positive at
2 months, higher default and failure rates, and lower cure
rates than the occasional interrupters.
Out of the total 148 patients, the sensitivity, specificity, po-
sitive predictive value and negative predictive value of smear
status at two months to predict failure of treatment was
100%, 58%, 27% and 100%, respectively.
Discussion
Persistent sputum smear positivity at 2 months may predict
poor treatment outcome, higher rates of treatment failure
and relapse [4,5]. It influences subsequent treatment to be gi-
ven to the patient [1–3]. In this study an attempt was made to
identify clinical, radiological and bacteriological risk factors
for sputum smear positivity at two months under field condi-
tions under the national program in Delhi, India. The patients
with persistent sputum positive at two months did not differ
with respect to their diabetes mellitus or HIV status, smoking,
alcohol intake and body mass index (Table 1) with those who
achieved sputum smear conversion. Earlier, Singla et al. also
reported that the presence of diabetes mellitus did not affect
smear positivity at two months [6]. Banu Rekha et al. (2007)
found that in new sputum smear positive patients with tuber-
culosis, the presence of diabetes mellitus, HIV seropositivity
and weight did not affect smear or culture positivity at twoult.
. 2 month P value for test Odds ratio (OR) 95% CI for OR
c
4.3 <0.001 2.38 1.03–5.5
6.5 <0.001 n.dd
4.8 <0.001 12.19 3.98–37.37
5.2 =0.001 4.85 1.84–12.75
0.4 =0.024 1.39 0.54–3.56
8.7 4.31 1.43–12.97
re contaminated and the remaining 115 had negative culture).
nthsa.
Cured Defaultb Failure Died Total
47 (63.5%) 6 (8.1%) 20 (27.0%) 1 (1.4%) 74
d,g 7 (25.9%) 3 (11.1%) 16 (59.3%) 1 (3.7%) 27
,e,g 40 (87%) 2 (4.3%) 4 (8.7%) 0 (0%) 46
74 (100.0%) 0 (0%) 0 (0%) 0 (0%) 74
ear positive at 2 monthsa.
ar negative at two months <0.001.
ear negative at three months <0.001.
Table 5 – Interruptions in treatment in cases and controls.
Variable Sm + 2 M (case) Sm  2 M (control) P for Xb Un-adjusted odds ratio (OR) 95% CI
N = 74 %a N = 74 %a
Interruption
in IP
Number of
interruptionsd
0 34 45.9 50 67.6 0.038 Reference categoryb
1 10 13.5 13 17.6 1.13 0.45–2.87
2 14 18.9 8 10.8 2.57 0.97–6.80
3 8 10.8 1 1.4 11.77 1.40–98.41
4 2 2.7 1 1.4 2.94 0.26–33.73
5 3 4.1 1 1.4 4.41 0.44–44.21
6 2 2.7 0 0 Not applicablec
7 1 1.4 0 0 Not applicablec
a Percentage out of cases or controls respectively.
b Non interrupter.
c Cannot be calculated due to zero value in controls.
d See Table 1 for occasional and frequent interrupters.
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mostly with pulmonary tuberculosis, in Hong Kong, ever
smokers were as likely as never smokers to have smear or cul-
ture positive results at the end of two months of treatment
[12].
Malnutrition or lower body mass index is known to lead to
reactivation of tuberculosis and poorer outcomes to treat-
ment [2,12–14]. In this study, lower BMI was associated with
being smear positive at two months in univariate analysis,
but not in multivariate analysis (Tables 2 and 3).
Patients whose initial sputum smear grade was 3+ were
more likely to be smear positive at 2 months as compared
with patients with lesser grades of sputum. However, this dif-
ference was not an independent predictor of smear positivity
at two months. Other larger retrospective studies done earlier
have shown that a higher initial sputum smear grade is asso-
ciated with being smear positive at two or three months
[5,6,15–17].
In this study, radiologically far advanced disease and cav-
ity were independently associated with smear positivity at
2 months of treatment (Tables 2 and 3). Cavity and extensive
disease harbor a higher bacterial load [18]. Singla et al.
(2003) have reported earlier that the presence of multiple cav-
ities on X-ray was associated with persistent smear positivity
at two months [6]. Cavities on chest X-ray have also been
associated with less patients’ culture converting by two
months [19].
The influence of interruption in treatment during the
intensive phase on sputum positivity at 2 months and on
treatment outcome under a national program has not been
analyzed before. This study (Tables 5 and 6) showed that fre-
quent interrupters (those who interrupted treatment thrice or
more) had significantly higher chances of being smear and
culture positive at 2 months; had higher default and failure
rates; and lower cure rates than the occasional interrupters
(who interrupted treatment only once or twice). The occa-
sional interrupters should be identified early lest they become
frequent interrupters, with adverse treatment outcomes. This
study demonstrated that there exists an operationally useful
differentiation of ‘occasional’ and ‘frequent’ interrupters’. Infuture studies, the precise cut-off and influence of the num-
ber of interruptions should be better elucidated.
The factors predicting sputum AFB smear positivity at
2 months of treatment among new TB patients also predicted
sputum AFB culture positivity at 2 months of treatment. This
shows the association of these factors with the presence of
live bacilli at 2 months, further strengthening the association
of these risk factors to delayed killing of bacilli.
In India, among new TB patients, MDR-TB is estimated to
be low: up to 3% [20]. Patients remaining sputum positive at
2 months also showed to be harboring higher levels of drug
resistant bacilli, including multidrug-resistant bacilli to the
level of 9.5% (see Figure). The interruptions during treatment
among patients remaining sputum positive at 2 months may
have led to amplification of drug resistance and could be the
reason for observed higher levels of MDR-TB at 2 months
among these patients.
Among patients who remain sputum positive at 2 months,
the intensive phase of treatment is extended for one more
month. Comparison of treatment outcome of patients whose
sputa were positive at two or three months with those who
achieved sputum conversion at two to three months (Table 4)
showed that the former group had lower cure rates and more
defaults, failures and deaths (P < 0.001, Fisher’s exact test).
These observations reaffirm earlier observations that sputum
positivity at two to three months of treatment is a predictor of
poor treatment outcome [4–6].
The sensitivity and specificity of smear positive status at
two months to predict failure of treatment was 100% and
58%, respectively, as compared with smear negative patients.
In a meta-analysis, Horne et al. (2010) found that there was
substantial heterogeneity in sputum status at 2 months pre-
dicting failure for sensitivity across 7 studies (v2 = 22.31, 6 df,
p = 0.001; I2 = 73.1%), making meaningful interpretation diffi-
cult. They concluded that although the sputum status at
two months may not be a good enough surrogate marker
for a poor outcome of treatment, these patients are more
likely to have a failure [21]. This study suggests that the pa-
tients remaining sputum positive at 2 months of treatment,
who are at a higher risk to fail treatment, form a focus group
Table 6 – Effect of treatment interruptions on sputum culture at 2 months, DST at 2 months and treatment outcome.
Factors Any interruption
in IP
No interruption
in IP
P value for testa Non-interrupter Occasional
interrupter
Frequent interrupter P value for test
n % n % n % n % n %
Cultureb Positive 17 27 13 15.9 0.101c 13 15.9 9 20.5 8 44.4 0.024c
DST analysisd Pan-sensitive 4 28.6 5 45.5 0.875e 5 45.5 1 14.3 3 42.9 0.704e
Resistant non-MDR 6 42.9 3 27.3 3 27.3 4 57.1 2 28.6
MDR 4 28.6 3 27.3 3 27.3 2 28.6 2 28.6
Treatment outcomef Cured 49 76.6 71 85.5 0.125e 71 85.5 37 84.1 11 57.9 0.038e
Default 5 7.8 1 1.2 1 1.2 2 4.5 3 15.8
Failure 10 15.6 10 11.9 10 11.9 5 11.4 5 26.3
Died 0 0 1 1.2 0 0 0 0
IP: Intensive phase.
a Comparing patients with any interruption to no interruptions in IP.
b Percentages for ‘any interruptions in IP’, ’no interruptions in IP’/ ‘non interrupter’, ‘occasional interrupter’ and ‘frequent interrupter’ are out of 63, 82, 44 and 18 respectively for whom useful culture
result (where culture was not contaminated and DST could also be done from culture) was available.
c Pearson’s chi square test.
d Out of a total 25 patients for whom useful DST results were available, percentages for ‘any interruptions in IP’, ’no interruptions in IP’, ‘non interrupter’, ‘occasional interrupter’ and ‘frequent
interrupter’ are out of 14, 11, 7 and 7 respectively.
e Fisher’s exact test.
f For treatment outcomes, percentages for ‘any interruptions in IP’, ’no interruptions in IP’/ ‘non interrupter’, ‘occasional interrupter’ and ‘frequent interrupter’ are out of 64, 84, 45 and 19 respectively.
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program.
This study was limited by its small sample size. There
were no patients who were smear negative at two months
and who had a culture positive or smear positive at three
months or poor outcome of treatment, making meaningful
comparison difficult.
To conclude, this study showed that under field conditions
duration of illness for more than 2 months, the presence of
cavity or extensive disease on chest X-ray, and interruptions
in intensive phase of treatment were significant independent
predictors of being smear/culture positive at two months.
Sputum positivity at two months is also associated with poor
treatment outcomes. An early identification of patients with
these risk factors may aid in care of individual patients,
achieving greater efficiency in resource utilization under the
program conditions, as well as in the evaluation of new tuber-
culosis therapeutics. The study also highlighted the plausible
influence of frequency of interruptions on adverse treatment
outcome, suggesting that regularity of treatment must be
ensured.
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